This post was originally published on this site Opdivo (nivolumab) continues to increase the long-term overall survival of patients with advanced non-small cell lung cancer (NSCLC) compared to the chemotherapy Taxotere (docetaxel), according to pooled data from two Phase 3 trials. The findings were presented in an oral presentation, titled “Five-Year Outcomes From the Randomized,…
This post was originally published on this site Nanospectra Biosciences‘ AuroLase Therapy, a focal therapy for prostate cancer that uses gold-silica nanoparticles, showed a good safety profile and evidence of successfully eliminating the cancer in a pilot clinical trial. Results were published in the journal PNAS, in the study, “Gold nanoshell-localized photothermal ablation of prostate tumors…
This post was originally published on this site Surgical treatment aimed at preserving fertility is just as effective, in terms of survival, as more aggressive surgery in treating early-stage ovarian cancer, a new study suggests. The study, “Fertility-sparing surgery for treatment of non-epithelial ovarian cancer: Oncological and reproductive outcomes in a prospective nationwide population-based cohort…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab), in combination with Velcade (bortezomib), thalidomide and dexamethasone (collectively known as VTd), to treat newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplant (ASCT). Darzalex is an antibody designed to recognize and block…
This post was originally published on this site I never knew what I wanted to do with my life. In fact, I’ve always been blatantly envious of people who do. I came from a family of nomadic artists, so I had a feeling I’d never be certain about my career. How could I know exactly…
This post was originally published on this site The first patients have been dosed in a Phase 1 trial evaluating Arvinas‘ experimental therapy ARV-471 for locally-advanced or metastatic ER-positive, HER2-negative breast cancer. Approximately 80% of newly-diagnosed breast cancers produce a protein called an estrogen receptor (ER). In these cancers, the hormone estrogen binds to its…
This post was originally published on this site Maintenance treatment with Clovis Oncology’s Rubraca (rucaparib) extends the time until disease progression in women with recurrent ovarian cancer, exploratory analysis from a Phase 3 trial shows. This occurs regardless of the patients’ response to prior treatment with platinum-based chemotherapy agents. The analysis will be presented at the…
This post was originally published on this site CLR 131, a a phospholipid drug conjugate (PDC) developed by Cellectar Biosciences, has been granted orphan drug status by the European Commission for the treatment of multiple myeloma, the company announced. The status follows the fast track designation granted in May by the U.S. Food and Drug Administration…
This post was originally published on this site Next month’s annual conference of the National Organization for Rare Disorders (NORD) in Washington, D.C., couldn’t come at a better time, says Marshall Summar, MD, chairman of NORD’s board of directors. “The pace of discovery in rare diseases has gone from brisk to hypersonic,” Summar told BioNews…
This post was originally published on this site Compass Self Storage has raised more than $100,000 this year for the Leukemia & Lymphoma Society (LLS), particularly for its children’s initiative. The $101,618 raised brings to more than $500,000 the amount Compass has donated over the years to LLS, including a local Ohio chapter. Compass is…
